Waters (WAT)
(Delayed Data from NYSE)
$352.51 USD
-1.89 (-0.53%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $352.48 -0.03 (-0.01%) 7:14 PM ET
4-Sell of 5 4
D Value F Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$352.51 USD
-1.89 (-0.53%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $352.48 -0.03 (-0.01%) 7:14 PM ET
4-Sell of 5 4
D Value F Growth A Momentum D VGM
Zacks News
Waters (WAT) Q1 Earnings Surpass Estimates, Sales Rise Y/Y
by Zacks Equity Research
Waters' (WAT) first-quarter results reflect gains from a strong momentum across pharmaceutical and industrial end-markets, and geographical regions.
Waters (WAT) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 20.69% and 9.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Waters (WAT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Waters' (WAT) first-quarter 2022 results are likely to reflect solid momentum across pharmaceutical, industrial, and academic and government end markets.
Plexus (PLXS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Plexus (PLXS) delivered earnings and revenue surprises of 14.46% and 5.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Waters (WAT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Waters (WAT) Expands Portfolio With Xevo TQ Absolute System
by Zacks Equity Research
Waters (WAT) unveils the Xevo TQ Absolute system, which is up to 15 times more sensitive, 45% smaller in size, and consumes up to 50% less electricity and gas supply.
Here's Why Waters (WAT) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Waters (WAT) Boosts Its LC-MS Efforts With Latest Software
by Zacks Equity Research
Waters (WAT) introduces the Intact Mass Software application on waters_connect and Waters MaxPeak Premier Protein BEH C4 300A Columns for biomolecule drug discovery and development.
Why Is Waters (WAT) Down 4.4% Since Last Earnings Report?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Waters (WAT) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Waters' (WAT) fourth-quarter results reflect gains from a strong momentum across end-markets and geographical regions.
Waters (WAT) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 5.76% and 1.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Waters (WAT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Waters' (WAT) fourth-quarter 2021 results are likely to reflect solid momentum across pharmaceutical and industrial end markets.
Analysts Estimate Waters (WAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Waters (WAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Waters (WAT) Boosts Mass Spectrometry Via MS Quan Application
by Zacks Equity Research
Waters (WAT) releases the MS Quan application on the waters_connect informatics software platform to help scientists efficiently screen large number of samples and contaminants.
Waters (WAT) Down 5.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Waters (WAT) Q3 Earnings & Revenues Beat Estimates, Rise Y/Y
by Shilpa Mete
Waters' (WAT) third-quarter results reflect gains from strong momentum across pharmaceutical and industrial end-markets.
Waters (WAT) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 13.68% and 1.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Waters (WAT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Waters' (WAT) third-quarter 2021 results are likely to reflect strength across liquid chromatography instruments and mass spectrometers.
Waters (WAT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Waters (WAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: Mettler-Toledo International, PerkinElmer and Waters Corp
by Zacks Equity Research
Zacks Industry Outlook Highlights: Mettler-Toledo International, PerkinElmer and Waters Corp
3 Stocks to Watch on Rising Demand for Scientific Instruments
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD), PerkinElmer (PKI) and Waters Corporation (WAT) are gaining from strong life science, pharmaceutical and academic end-market demand as well as rising healthcare spending.
Waters (WAT) BioAccord System to Expand Portfolio Offerings
by Zacks Equity Research
Waters (WAT) introduces Waters BioAccord System with ACQUITY Premier for seamless monitoring of attributes of biotherapeutics.
Waters (WAT) Up 5.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Waters (WAT) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Waters (WAT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Can Waters (WAT) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Waters (WAT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.